Skip to main navigation Skip to search Skip to main content

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

C J Tyrrell, A V Kaisary, P Iversen, J B Anderson, L Baert, T Tammela, M Chamberlain, A Webster, G Blackledge

    293 Citations (Scopus)

    Abstract

    To evaluate the efficacy and tolerability of 'Casodex' monotherapy (150 mg daily) for metastatic and locally advanced prostate cancer.
    Original languageEnglish
    JournalEuropean Urology
    Volume33
    Issue number5
    Pages (from-to)447-56
    Number of pages10
    ISSN0302-2838
    Publication statusPublished - 1998

    Keywords

    • Aged
    • Aged, 80 and over
    • Androgen Antagonists
    • Anilides
    • Bone Neoplasms
    • Castration
    • Humans
    • Male
    • Middle Aged
    • Neoplasm Metastasis
    • Neoplasm Staging
    • Nitriles
    • Probability
    • Prognosis
    • Prostate-Specific Antigen
    • Prostatic Neoplasms
    • Quality of Life
    • Survival Rate
    • Tosyl Compounds
    • Treatment Outcome

    Fingerprint

    Dive into the research topics of 'A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer'. Together they form a unique fingerprint.

    Cite this